Beneficial Ownership Report · SCHEDULE 13G/A
Eikon Therapeutics, Inc.
EIKNNASDAQEQUITYCurrent
Beneficial Ownership Report
Structured filing — SCHEDULE 13G/A
primary_doc.xml
Amendment · This filing reports the amendment as submitted.
Subject company
- Company
- Eikon Therapeutics, Inc.
- Company CIK
- 0001861123
- Street
- 230 Harriet Tubman Way,
- City
- Millbrae
- State / country code
- CA
- Postal code
- 94030
Statement details
- Amendment number
- 1
- Security class
- Common Stock, par value $0.0001 per share
- Event date
- 09/30/2026
- Rule designation
- Rule 13d-1(c)
Reporting person 1
- Name
- Abu Dhabi Investment Authority
- Citizenship / organization
- C0
- Reporting person type
- OO
- Aggregate amount owned
- 1,147,138.00
- Percent of class
- 2.1
- Sole voting power
- 0.00
- Shared voting power
- 1,147,138.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 1,147,138.00
- Aggregate excludes certain shares
- N
- Comments
- (1) The percent calculation is based on 54,165,030 shares of Common Stock outstanding as of August 3, 2026, as disclosed in Eikon Therapeutics, Inc.'s Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2026, filed with the U.S. Securities and Exchange Commission (the "SEC") on August 13, 2026 (the "Form 10-Q").
Reporting person 2
- Name
- Platinum Falcon B 2018 RSC Limited
- Citizenship / organization
- C0
- Reporting person type
- CO
- Aggregate amount owned
- 1,147,138.00
- Percent of class
- 2.1
- Sole voting power
- 0.00
- Shared voting power
- 1,147,138.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 1,147,138.00
- Aggregate excludes certain shares
- N
- Comments
- (1) Platinum Falcon B 2018 RSC Limited ("Platinum Falcon") is the direct owner of 1,147,138 of the shares of Common Stock reported herein. Platinum Falcon is a wholly owned subsidiary of Abu Dhabi Investment Authority. Pursuant to the rules and regulations of the SEC, Abu Dhabi Investment Authority may be deemed to be the beneficial owner of the shares of Common Stock directly held by Platinum Falcon. (2) The percent calculation is based on 54,165,030 shares of Common Stock outstanding as of August 3, 2026, as disclosed in Eikon Therapeutics, Inc.'s Form 10-Q.
Item 1
Issuer
Eikon Therapeutics, Inc.
Principal executive office address
230 Harriet Tubman Way, Millbrae CA 94030
Item 2
Citizenship
1. Abu Dhabi Investment Authority (ADIA) is a public institution established by the Government of the Emirate of Abu Dhabi in 1976 as an independent investment institution. 2. Platinum Falcon B 2018 RSC Limited is a restricted scope company organized under the laws of the Abu Dhabi Global Market, Abu Dhabi, United Arab Emirates.
Filing person
This Schedule 13G/A is being filed on behalf of the following: 1. Abu Dhabi Investment Authority 2. Platinum Falcon B 2018 RSC Limited
Principal business or residence address
The principal business address of each of the Reporting Persons is as follows: 1. 211 Corniche Street P.O. Box 3600 Abu Dhabi, United Arab Emirates 3600 2. Level 26, Al Khatem Tower Abu Dhabi Global Market Square Al Maryah Island, Abu Dhabi United Arab Emirates
Item 4
Percent of class
See responses to Item 11 on each cover page.
Amount beneficially owned
See responses to Item 9 on each cover page.
Sole voting power
See responses to Item 5 on each cover page.
Shared voting power
See responses to Item 6 on each cover page.
Sole dispositive power
See responses to Item 7 on each cover page.
Shared dispositive power
See responses to Item 8 on each cover page.
Item 5
Not applicable indication
N
Ownership of 5% or less
Y
Item 6
Not applicable indication
Y
Item 7
Not applicable indication
Y
Item 8
Not applicable indication
Y
Item 9
Not applicable indication
Y
Item 10
Not applicable indication
N
Certifications
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
Signature 1
- Reporting person
- Abu Dhabi Investment Authority
- Signed
- /s/ Saif Almashghouni · /s/ Ahmed AlNeyadi
- Title
- Saif Almashghouni / Authorized Signatory · Ahmed AlNeyadi / Authorized Signatory
- Date
- 10/02/2026 · 10/02/2026
Signature 2
- Reporting person
- Platinum Falcon B 2018 RSC Limited
- Signed
- /s/ Saif Almashghouni · /s/ Ahmed AlNeyadi
- Title
- Saif Almashghouni / Authorized Signatory · Ahmed AlNeyadi / Authorized Signatory
- Date
- 10/02/2026 · 10/02/2026
Company context
We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications. We believe our product candidates reflect strong scientific and clinical potential and could eventually become critical medicines in the treatment paradigm of various cancers.